G Wikholm1. 1. Section for Interventional Neuroradiology, Sahlgrenska University Hospital, Göteborg, Sweden.
Abstract
PURPOSE: To verify the permanence of total occlusion of cerebral arteriovenous malformations after embolization with N-butyl cyano-acrylate and to evaluate the occlusion rate. METHODS: One hundred thirty-four patients were treated for cerebral arteriovenous malformations with N-butyl cyano-acrylate embolization after superselective catheterization. Those initially totally occluded have been followed with angiography. RESULTS: In 15 instances (11.2%) the arteriovenous malformations were totally occluded by embolization alone. Follow-up angiograms have been performed in 12 cases (80%) after 4 to 78 (mean, 27) months after embolization. In all instances the arteriovenous malformations have remained occluded, and there have been no clinical signs of activity. CONCLUSION: After total occlusion of a cerebral arteriovenous malformation with N-butyl cyano-acrylate, the lesion stays occluded, and the clinical course seems stable.
PURPOSE: To verify the permanence of total occlusion of cerebral arteriovenous malformations after embolization with N-butyl cyano-acrylate and to evaluate the occlusion rate. METHODS: One hundred thirty-four patients were treated for cerebral arteriovenous malformations with N-butyl cyano-acrylate embolization after superselective catheterization. Those initially totally occluded have been followed with angiography. RESULTS: In 15 instances (11.2%) the arteriovenous malformations were totally occluded by embolization alone. Follow-up angiograms have been performed in 12 cases (80%) after 4 to 78 (mean, 27) months after embolization. In all instances the arteriovenous malformations have remained occluded, and there have been no clinical signs of activity. CONCLUSION: After total occlusion of a cerebral arteriovenous malformation with N-butyl cyano-acrylate, the lesion stays occluded, and the clinical course seems stable.
Authors: José A Jordan; Juan Carlos Llibre; Frank Vázquez; Raúl Rodríguez; José A Prince; José Carlos Ugarte Journal: Interv Neuroradiol Date: 2014-02-10 Impact factor: 1.610
Authors: J O Heidenreich; S Hartlieb; R Stendel; T A Pietilä; P Schlattmann; K-J Wolf; A M Schilling Journal: AJNR Am J Neuroradiol Date: 2006-02 Impact factor: 3.825
Authors: Matthew J Gounis; Baruch B Lieber; Ajay K Wakhloo; Ralf Siekmann; L N Hopkins Journal: AJNR Am J Neuroradiol Date: 2002 Jun-Jul Impact factor: 3.825